5 edition of Drug resistance in mycobacteria found in the catalog.
Includes bibliographical references and index.
|Statement||Pattisapu Rama Jogi Gangadharam.|
|LC Classifications||QR82.M8 G36 1984|
|The Physical Object|
|Pagination||167 p. :|
|Number of Pages||167|
|LC Control Number||83003702|
1. INTRODUCTION. Drug-resistant tuberculosis (TB) remains a main hurdle for national tuberculosis control programs. As per the estimates of World Health Organization (WHO), in , the multidrug-resistant (MDR) TB/rifampicin-resistant (RR) TB was 19% in previously treated patients and % in newly diagnosed TB patients .The diagnosis of drug resistance for first-line antitubercular drugs Author: Sunil Sethi, Priyanka Agarwal, Rajiv Khaneja, Naresh Kumar, Nitin Kumar, Jagesh Chandna, Ashutosh Na. Clinically relevant drug resistance in Mycobacterium tuberculosis occurs mainly by the acquisition of spontaneous chromosomal mutations that alter the drug target or the prodrug-activating enzymes, followed by the selection of drug-resistant mutants that may occur in the case of exposure to monotherapy or lower antibiotic doses due to inadequate prescription, poor patient compliance, and Cited by:
A critical review of the current and most recent advances in the genomics and molecular biology of mycobacteria. Focuses on the topical and most relevant aspects. Includes strain variation and evolution, hypervirulent strains, electron transport and respiration, lipid biosynthesis, DNA repair, oxygen signaling, sulphur metabolism, protein secretion, the protein kinase family. These drugs are used to treat all persons with TB disease. What is extensively drug resistant tuberculosis (XDR TB)? Extensively drug resistant TB (XDR TB) is a rare type of MDR TB that is resistant to isoniazid and rifampin, plus any fluoroquinolone and at least one of three injectable second-line drugs (i.e., amikacin, kanamycin, or capreomycin).
Tuberculosis (TB) is a serious public health problem worldwide. Its situation is worsened by the presence of multidrug resistant (MDR) strains of Mycobacterium tuberculosis, the causative agent of the disease. In recent years, even more serious forms of drug resistance have been reported. A better knowledge of the mechanisms of drug resistance of M. tuberculosis and the relevant molecular Cited by: In many bacteria, drug-resistance determinants are carried on mobile genetic elements. However, in Mycobacterium tuberculosis (Mtb), drug resistance is exclusively associated with point mutations and chromosomal rearrangements. Poor or intermittent therapy has long been thought to be the major explanation for drug resistance, and it is believed that drug-resistant strains develop Cited by: 3.
Index numbers of Indian prices, 1861-1918
Austria and the United States, 1848-1852
Foundation - Autumn Box 62.
Ohio W-R globe
Annotations to the readable homeowners forms section II liability coverages.
Garment trades news [dummy issue] - National Union of Tailors and Garment Workers.
File under: arson
Alcohol and Anxiety
Mozart and the sonata form
Metabolism in Mycobacterium leprae, M. tuberculosis and other pathogenic mycobacteria Antigen specificity and function of human T lymphocyte clones reactive with mycobacteria Related articles inCited by: MDR-TB is caused by strains of Mycobacterium tuberculosis that are resistant to at least rifampicin and isoniazid, two key drugs in the treatment of the disease.
Sinceit has been recognized the presence of even more resistant strains of M. tuberculosis labelled as extensively drug resistant (XDR)-TB [ 2, 3, 4 ].Cited by: The emergence and spread of drug-resistant Mycobacterium tuberculosis is of global concern.
To improve the understanding of drug resistance in Mycobacteria, numerous studies have been performed to discover diagnostic markers and genetic determinants associated with resistance to anti-tuberculosis drug. However, the related information is scattered in a massive body of literature, which is inconvenient for researchers to investigate the molecular mechanism of drug : Enyu Dai, Hao Zhang, Xu Zhou, Qian Song, Di Li, Lei Luo, Xinyu Xu, Wei Jiang, Hong Ling.
Jovita Marcinkeviciene. W R Jacobs. Isoniazid (INH) is a highly effective drug used in the treatment and prophylaxis of Mycobacterium tuberculosis infections. Resistance to INH in clinical. Tuberculosis Drug resistance in mycobacteria book, an infectious disease caused by the bacterium Mycobacterium tuberculosis (Mtb), has burdened vulnerable populations in modern day societies for decades.
Recently, this global health threat has been heightened by the emergence and propagation of multi drug-resistant (MDR) and extensively drug-resistant (XDR) strains of Mtb Cited by: 3.
Multidrug-resistant (MDR) tuberculosis (TB), defined as infection with Mycobacterium tuberculosis that is resistant to isoniazid and rifampin, can be transmitted and manifest as a primary infection without a patient having received those medications or can be acquired by the patient during drug therapy.
A person may be initially infected with > 1 M. tuberculosis strain with different patterns. Introduction. Resistance to anti-TB drugs is an escalating global health crisis.
The global burden of TB remains alarmingly high, with ∼ million incident cases and ∼ million deaths reported by the WHO in 1, Mycobacterium tuberculosis (MTB) strains displaying in vitro resistance to isoniazid and rifampicin accounted for ∼ incident cases and deaths in 1 Cited by: • Detects drug resistance or confirms the emergence of drug resistance • Offers insight into appropriate treatment for contacts of patients with active TB • Used to estimate the prevalence of primary and acquired drug resistance in a community 18File Size: KB.
Its situation is worsened by the presence of multidrug resistant (MDR) strains of Mycobacterium tuberculosis, the causative agent of the disease. In recent years, even more serious forms of drug. therapy to slow down the development of drug resistance in mycobacteria. Drug Resistant Tuberculosis Multi drug resistant tuberculosis is resistant to first line drugs Isoniazid and Rifampicin.
The term MDR-TB was associated with high mortality rates occurred among HIV. All but one of the four major mechanisms of resistance to antimicrobial agents—inactivation of the drug, altered cell wall permeability or drug efflux, drug titration due to target overproduction, and alteration of the target by mutation—appear to be employed by Mycobacterium tuberculosis in its resistance to components of short course chemotherapy by: Prevalence and drug resistance of mycobacteria in Turkish cystic fibrosis patients Dilek Satana, 1 Gonca Erkose-Genc, 1 Zeynep Tamay, 2 Meltem Uzun, 1 Nermin Guler, 2 and Zayre Erturan 1 1 Istanbul Faculty of Medicine, Department of Medical Microbiology, Istanbul Cited by: 2.
Over cases of multidrug-resistant (MDR) tuberculosis (TB) occur every year globally, 9% of them being affected by extensively drug-resistant (XDR) strains of Mycobacterium tuberculosis.
Extensively Drug-resistant TB (XDR TB) Extensively drug-resistant TB (XDR TB) is a rare type of MDR TB that is resistant to isoniazid and rifampin, plus any fluoroquinolone and at least one of three injectable second-line drugs (i.e., amikacin, kanamycin, or capreomycin).
Tuberculosis (TB), an infectious disease caused by the bacterium Mycobacterium tuberculosis (Mtb), has burdened vulnerable populations in modern day societies for ly, this global health threat has been heightened by the emergence and propagation of multi drug-resistant (MDR) and extensively drug-resistant (XDR) strains of Mtb that are resistant to current treatment regimens.
Non-tuberculous Mycobacterium species (NTM) cause disease in diverse animals as well as in susceptible humans. Antiretroviral therapy has decreased AIDS-associated NTM in many settings; however, the reported incidence of M.
avium complex (MAC) infection of non-AIDS patients has increased in recent years, especially among women (1–4). Most NTMs are slowly growing mycobacteria Cited by: 1. Nontuberculous Mycobacteria (NTM): Microbiological, Clinical and Geographical Distribution is a complete reference that stimulates a greater understanding of NTM infections.
Sections cover microbiologic and molecular diagnostic tools, drug susceptibility tests, human genetic susceptibility, prevalence and incidence studies, clinical and radiological presentations, and clinical trials for.
drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria. Clin Microbiol Rev – doi: /CMR Cai Y, Chai D, Wang R, Liang B, Bai N ( Pyrazinamide (PZA) is an indispensable first-line drug used for the treatment of TB.
It plays a key role in reducing TB relapse rates, shortening the course of the disease treatment from 9–12 months to 6 months, and the treatment of patients infected with bacillary strains that are resistant Cited by: Abstract. Persistence, manifested as drug tolerance, represents a significant obstacle to global tuberculosis control.
The bactericidal drugs isoniazid and rifampicin kill greater than 99% of exponentially growing Mycobacterium tuberculosis (Mtb) cells, but the remaining cells are persisters, cells with decreased metabolic rate, refractory to killing by these drugs, and able to generate drug Cited by:.
Whole-genome and targeted sequencing of drug-resistant Mycobacterium tuberculosis on the iSeq and MiSeq: A performance, ease-of-use, and cost evaluation. Rebecca E. Colman, Aurélien Mace, Marva Seifert, Jonathan Hetzel, Haifa Mshaiel, Anita Suresh, Darrin Lemmer, David M.
Engelthaler, Donald G. Cited by: 2. Abstract. Antibiotic-resistant Mycobacterium tuberculosis strains are threatening progress in containing the global tuberculosis cterium tuberculosis is intrinsically resistant to many antibiotics, limiting the number of compounds available for treatment.
This intrinsic resistance is due to a number of mechanisms including a thick, waxy, hydrophobic cell envelope and Cited by: Additional Physical Format: Online version: Gangadharam, Pattisapu Rama Jogi, Drug resistance in mycobacteria.
Boca Raton, Fla.: CRC Press, ©